Phase I Clinical Trial Using an Engineered Peripheral Blood Graft for Haploidentical Transplantation
The Phase I trial conducted by M.D. Anderson Cancer Center explores the safety and efficacy of an engineered peripheral blood graft for haploidentical transplantation in patients with high-risk hematologic malignancies. Given the increasing incidence of hematologic cancers and the limitations of current transplant options, this study addresses a significant unmet medical need. The results could position the sponsor favorably in the competitive landscape of stem cell transplantation, particularly against established therapies. The collaboration with the National Cancer Institute (NCI) may enhance credibility and facilitate future funding opportunities. Market implications include potential licensing agreements or partnerships if the trial demonstrates favorable outcomes, particularly in reducing GVHD, which remains a major complication in transplant procedures.
Indication: Acute Lymphoblastic Leukemia
Modality: small molecule
Target: Engineered T cells from haploidentical donors aimed at reducing graft-versus-host disease (GVHD) in hematologic malignancies.
Sponsor: M.D. Anderson Cancer Center
Source URL: ClinicalTrials.gov
Source updated: Feb 16, 2023
Ingested: Jun 18, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Engineered T cells from haploidentical donors aimed at reducing graft-versus-host disease (GVHD) in hematologic malignancies.
View original source fields
Condition raw: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Aplastic Anemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Plasma Cell Myeloma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Therapy-Related Myelodysplastic Syndrome
Condition normalized: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Aplastic Anemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Plasma Cell Myeloma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Therapy-Related Myelodysplastic Syndrome
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Engineered T cells from haploidentical donors aimed at reducing graft-versus-host disease (GVHD) in hematologic malignancies.
Target normalized: Engineered T cells from haploidentical donors aimed at reducing graft-versus-host disease (GVHD) in hematologic malignancies.